GSK’s Garnier Touts “Progressive Blockbuster” As Model For Future Drugs

One way to handle an increasingly cautious FDA would be to take a different tack on development - pursuing "progressive blockbusters" that are approved on a population-by-population basis to prove the drugs are safe in different patient types rather than trying to make a traditional blockbuster big splash, according to GlaxoSmithKline CEO JP Garnier